Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
1705
¥ million (increase in operating loss versus the forecast for the fiscal year ending January 2026)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateOperating profit+43.5%
基準 3,920Target5,625million yen
Net income for the current fiscal year+39.3%
基準 4,045Target5,635million yen
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Key initiatives
01Making Japan the central hub
02Realizing the US business
03Achieving success in cerebral infarction treatment
04Building the supply chain
05SanBio Smart Regional Healthcare Collaboration Initiative
Plan assumptionsUS dollar exchange rate for the fiscal year ending January 2027: ¥150.00 (forecast for the fiscal year ending January 2026: ¥148.00)
Size of the Target MarketDescription Patient populations with chronic-phase TBI, chronic-phase cerebral infarction and chronic-phase cerebral hemorrhage are presented for multiple regions and markets / Figures Chronic-phase TBI: 6.57 million, 11.00 million, 60,000 and 5.51 million / chronic-phase cerebral infarction: 3.01 million, 15.73 million, 1.19 million and 6.85 million / chronic-phase cerebral hemorrhage: 600,000, 1.50 million, 200,000 and 1.02 million / Source Company analysis based on multiple publications, Arch Neurol. 1986;43(6):570-572 (Wang et al.), Circulation. 2017;135:759-771 (Wang et al., 2017), GHDx Healthdata IQVIA analysis 2020, Ministry of Health, Labour and Welfare, Patient Survey 2020
Risks identified by the company
Uncertainty in new drug development / risks related to the development and manufacture of regenerative cell therapies
Dependence on External Service Providers
Compliance
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Progress against the plan | Annual update |
| Operating profit target | ▲3,920 (forecast for the fiscal year ending January 2026) → ▲5,625 (forecast for the fiscal year ending January 2027)（Not calculable (the comparison figure is a loss)） |
| Net income target | ▲4,045 (forecast for the fiscal year ending January 2026) → ▲5,635 (forecast for the fiscal year ending January 2027)（Not calculable (the comparison figure is a loss)） |
| Plan assumptions | US dollar exchange rate for the fiscal year ending January 2027: ¥150.00 (forecast for the fiscal year ending January 2026: ¥148.00) |
| Key initiatives | Making Japan the central hub, Realizing the US business, Achieving success in cerebral infarction treatment, Building the supply chain, SanBio Smart Regional Healthcare Collaboration Initiative |
| Size of the Target Market | Description Patient populations with chronic-phase TBI, chronic-phase cerebral infarction and chronic-phase cerebral hemorrhage are presented for multiple regions and markets / Figures Chronic-phase TBI: 6.57 million, 11.00 million, 60,000 and 5.51 million / chronic-phase cerebral infarction: 3.01 million, 15.73 million, 1.19 million and 6.85 million / chronic-phase cerebral hemorrhage: 600,000, 1.50 million, 200,000 and 1.02 million / Source Company analysis based on multiple publications, Arch Neurol. 1986;43(6):570-572 (Wang et al.), Circulation. 2017;135:759-771 (Wang et al., 2017), GHDx Healthdata IQVIA analysis 2020, Ministry of Health, Labour and Welfare, Patient Survey 2020 |
| Risks identified | Uncertainty in new drug development / risks related to the development and manufacture of regenerative cell therapies, Dependence on External Service Providers, Compliance |
| Publication date | 23 April 2026 |
Items this document does not state (16)
Plan periodSales TargetOperating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company stated that the main business expenses would be the costs of establishing manufacturing, distribution and sales systems for the rollout of Akugo®, as well as costs associated with activities toward approval. It also explained that, to achieve further growth, it would establish a growth platform in Japan at an early stage and maximize product value through global expansion.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.